Renovorx, INC 8-K filings

RenovoRx announced record second quarter 2026 results with 61% sequential revenue growth, raised full-year revenue guidance to $3.75M-$4.25M, and achieved full enrollment in its Phase III TIGeR-PaC trial.

RenovoRx announced its participation in a key opinion leader webinar discussing pancreatic cancer and its TAMP platform, scheduled for August 13, 2026.

RenovoRx, Inc. has received an additional 180-day period from Nasdaq to regain compliance with the minimum bid price requirement for continued listing.

RenovoRx, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of directors, approval of an incentive plan amendment, and ratification of its independent auditor.

RenovoRx announced its full year 2025 financial results, reporting $1.1 million in RenovoCath revenue and progress in its Phase III TIGeR-PaC trial, alongside a strengthened balance sheet.

RenovoRx, Inc. formally appointed Dr. Ramtin Agah as Executive Chairman, effective February 27, 2026, alongside his Chief Medical Officer role, with a new compensation package.

RenovoRx, Inc. announced an oversubscribed $10 million private placement of common stock and warrants, aiming to accelerate commercialization and advance its Phase III clinical trial.

RenovoRx, Inc. announced the appointment of Mark Voll, an experienced public company executive, as its new Chief Financial Officer, effective February 4, 2026, following the voluntary resignation of Ronald B. Kocak as Principal Accounting Officer.

RenovoRx, Inc. received a deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price, initiating a 180-day compliance period.

RenovoRx, Inc. entered into a Capital on Demand Sales Agreement to sell up to $3.7 million of common stock through an at-the-market offering.

RenovoRx announced its third quarter 2025 financial results, reporting approximately $900,000 in year-to-date revenue and $10 million in cash, alongside updates on RenovoCath commercialization and Phase III TIGeR-PaC trial progress.

RenovoRx announced strong Q2 2025 commercial revenue for its RenovoCath device and a positive independent Data Monitoring Committee recommendation to continue its pivotal Phase III TIGeR-PaC trial.

RenovoRx, Inc. announced that its stockholders approved all three proposals at the 2025 annual meeting, including the election of directors, an amendment to the equity incentive plan, and the ratification of its independent auditor.

RenovoRx announces strong Q1 2025 results with RenovoCath revenues exceeding expectations and continued progress in the TIGeR-PaC clinical trial.

RenovoRx announces initial revenues from RenovoCath commercialization, provides an update on the TIGeR-PaC clinical trial, and reports its 2024 financial results, including a $7.2 million cash position and $12.1 million in gross proceeds from a February 2025 offering.

RenovoRx has priced a $12.1 million underwritten public offering to advance its cancer therapies and commercialize its RenovoCath delivery platform.

RenovoRx reported its Q3 2024 financial results, highlighting progress in its Phase III clinical trial and commercialization plans for its RenovoCath delivery system.

RenovoRx is increasing production of its FDA-cleared RenovoCath delivery system due to strong demand from oncologists and interventional radiologists, while also exploring standalone commercial opportunities.

RenovoRx has appointed Frank, Rimerman + Co. LLP as its new independent auditor after Baker Tilly US, LLP resigned following the filing of the Q2 2024 report.

RenovoRx, Inc. has entered into a Change in Control and Severance Agreement with its Vice President, Controller, and Principal Accounting Officer, and held its 2024 annual meeting of stockholders.

RenovoRx has announced the resignation of its auditor, Baker Tilly US, LLP, and adjustments to executive compensation, including salary increases and bonuses following a recent equity financing.

RenovoRx has regained compliance with Nasdaq's minimum stockholders' equity requirement following a successful $17.2 million capital raise.

RenovoRx believes it has regained compliance with Nasdaq's minimum equity requirement following a recent $11.1 million private placement.

RenovoRx has successfully closed an $11.1 million private placement, bringing total gross proceeds raised since the start of 2024 to $17.2 million, which is expected to fund operations into 2026.

RenovoRx has successfully raised $11.1 million through a private placement, extending its cash runway into 2026 and supporting the advancement of its Phase III TIGeR-PaC trial.

RenovoRx has appointed Leesa Gentry as Chief Clinical Officer, with an annual base salary of $325,000 and a stock option grant.

RenovoRx is facing potential delisting from the Nasdaq due to not meeting minimum stockholders' equity requirements, despite a recent $6.1 million capital raise, and has appointed a new Chief Clinical Officer following the resignation of the previous COO.

RenovoRx, Inc. has appointed Ronald B. Kocak as Vice President, Controller and Principal Accounting Officer, following the resignation of James Ahlers as CFO.

RenovoRx has successfully closed a $6.1 million private placement, bolstering its financial position to advance its pivotal TIGeR-PaC Phase III clinical trial.